Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-128 vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Intravascular use for computed tomography (CT) imaging,Intravenous urography,Intra-arterial angiography (including coronary, peripheral, and cerebral),Ventriculography,Myelography (subarachnoid injection for spinal imaging),Off-label: Arthrography, hysterosalpingography (though not FDA-approved for these)
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 m L/min).
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Iopamidol is not metabolized and is excreted unchanged almost entirely by the kidneys via glomerular filtration. No hepatic metabolism or significant protein binding occurs.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Minimal protein binding (<5%), primarily to albumin.
97–99% (sex hormone-binding globulin and albumin)
Approximately 0.2-0.3 L/kg, reflecting distribution into extracellular fluid.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Not applicable for oral route (no oral formulation); 100% bioavailability via intravenous or intra-arterial administration.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
GFR <30 m L/min: use lowest feasible dose; GFR <15 m L/min: avoid use unless essential; consider hydration and N-acetylcysteine.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of contrast-induced nephropathy.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Neonates: 0.5-1 m L/kg IV; Infants/Children: 1-2 m L/kg IV (max 125 m L per dose) for contrast-enhanced CT.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Reduce dose to lowest effective (e.g., 50-100 m L); ensure adequate hydration; monitor renal function pre and post administration.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Iodinated contrast media including iopamidol are associated with an increased risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing renal impairment, particularly those with diabetes, volume depletion, or concurrent use of nephrotoxic drugs. Strict adherence to hydration protocols and renal monitoring is required.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Risk of contrast-induced nephropathy (CIN): Monitor renal function before and after administration, ensure adequate hydration, and avoid concurrent nephrotoxic agents.,Severe hypersensitivity reactions (e.g., anaphylaxis, bronchospasm): Have resuscitation equipment available; premedication may be considered for patients with known contrast allergy.,Thyroid dysfunction: Iodinated contrast may induce hyperthyroidism or hypothyroidism; caution in patients with thyroid disease.,Cardiovascular events: In patients with heart failure, coronary artery disease, or pulmonary hypertension, contrast media can cause hemodynamic instability, arrhythmias, or myocardial ischemia.,Neurologic effects: Intrathecal administration may cause seizures, arachnoiditis, or aseptic meningitis; use lowest possible dose and monitor for neurotoxicity.,Extravasation: Risk of tissue necrosis; administer through a secure IV line and monitor injection site.
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Absolute: Known hypersensitivity to iopamidol, other iodine-containing contrast media, or any component of the formulation.,Absolute: Intrathecal administration in patients with significant thrombophlebitis or infection at the injection site.,Relative: Pre-existing renal impairment (e GFR <30 m L/min/1.73m²) unless benefits outweigh risks; consider alternative imaging.,Relative: Multiple myeloma, pheochromocytoma, sickle cell disease (due to risk of vaso-occlusive events).,Relative: Pregnancy (especially first trimester) unless essential for diagnosis.
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
No specific food interactions. However, patients are often advised to maintain adequate hydration. Avoid alcohol consumption for 24 hours before and after the procedure as it may increase risk of dehydration. No dietary restrictions required.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is a theoretical risk of fetal hypothyroidism due to free iodide, but clinical evidence does not show a significant increase in congenital anomalies. Second and third trimester exposure is associated with transient neonatal hypothyroidism if the agent crosses the placenta, but no structural teratogenic effects are documented. The FDA assigns a Pregnancy Category B for iodinated contrast agents.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Iopamidol is excreted into breast milk in very small amounts. The milk-to-plasma (M/P) ratio is approximately 0.04–0.08 based on limited studies. The absolute dose received by a nursing infant is estimated to be less than 0.01% of the maternal dose, which is clinically insignificant. Therefore, breastfeeding can be continued without interruption, although some experts suggest discarding milk for 24 hours post-administration as a precaution. No adverse effects on the infant have been reported.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
No dosing adjustments are required for iopamidol (ISOVUE-128) during pregnancy based on pharmacokinetic changes. However, because physiological changes in pregnancy (increased plasma volume, increased renal clearance) may affect contrast agent distribution and elimination, the standard dose should be used based on body weight and indication. The lowest effective dose should be administered to minimize fetal exposure. No specific dose modifications are recommended in guidelines.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
ISOVUE-128 (iopamidol) is a nonionic, low-osmolality contrast medium. Pre-warming to body temperature reduces viscosity and improves patient tolerance. Risk of contrast-induced nephropathy (CIN) increases with pre-existing renal impairment; assess renal function (e GFR) prior to administration. Adequate hydration is critical. Monitor for delayed hypersensitivity reactions (up to 7 days). Metformin should be withheld for 48 hours post procedure if renal function is compromised. Have emergency equipment available for anaphylactoid reactions.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Inform your healthcare provider if you have any allergies, especially to contrast media or iodine.,Tell your provider about all medications you take, particularly metformin or any kidney-affecting drugs.,You may be asked to drink extra fluids before and after the procedure to protect your kidneys.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you have diabetes and take metformin, your doctor may advise stopping it for 48 hours after the scan.,Sensation of warmth, a metallic taste, or nausea during injection is common and usually resolves quickly.,After the procedure, you can resume normal diet unless directed otherwise.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-128 vs ANDROID 25, answered by our medical review team.
ISOVUE-128 is a Contrast Media that works by Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-128 and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-128 is: Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-128 and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-128 is classified as Category C. Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is . ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.